T细胞免疫球蛋白和黏蛋白结构域3及其单抗在肿瘤中的临床应用现状  

Clinical application status of T cell immunoglobulin and mucin domain-containing protein 3 and its monoclonal antibody in tumor

作　　者：高舒玥 赵飞宇 范润佳 程家敏 千年松 GAO Shuyue;ZHAO Feiyu;FAN Runjia;CHENG Jiamin;QIAN Niansong(Chinese People′s Liberation Army Medical School,Beijing,100853;Department of Hepatological Medicine,the Fifth Medical Center of General Hospital of People′s Liberation Army,Beijing,100853;Department of Respiratory and Critical Care Medicine,the Eighth Medical Center of General Hospital of Chinese People′s Liberation Army,Beijing,100853;Department of Oncology,Hainan Hospital of General Hospital of People′s Liberation Army,Sanya,Hainan,572000)

机构地区：[1]解放军医学院,北京100853 [2]中国人民解放军总医院第五医学中心肝病医学部,北京100853 [3]中国人民解放军总医院第八医学中心呼吸与危重症医学部,北京100853 [4]解放军总医院海南医院肿瘤内科,海南三亚572000

出　　处：《实用临床医药杂志》2023年第24期132-137,共6页Journal of Clinical Medicine in Practice

摘　　要：T细胞免疫球蛋白和黏蛋白结构域3(Tim-3)是TIM家族中的一员,广泛表达于各种细胞表面,可以参与自身免疫、感染和癌症等疾病的发生发展。临床试验发现联合阻断Tim-3和程序性死亡蛋白-1(PD-1)可提高晚期癌症患者的抗癌免疫反应水平,消退肿瘤。本文就Tim-3的基本生物学结构、相应配体和其在肿瘤微环境中的作用进行综述,以及总结正在进行的药物临床试验,这些数据表明Tim-3可以作为一个具有潜在意义的免疫检查点受体应用于未来抗肿瘤治疗中。T cell immunoglobulin and mucin domain-containing protein 3(Tim-3)is a member of the Tim family,which is widely expressed on the surface of various cells and can be involved in the occurrence and development of diseases such as autoimmune,infection and cancer.Clinical trials have found that a combination of blocking Tim-3 and programmed cell death 1(PD-1)can improve the anti-cancer immune response and regression of tumors in patients with advanced cancer.This article reviewed the basic biological structure of Tim-3,corresponding ligand and its role in tumor microenvironment,and summarized the ongoing clinical trials of TIM-3.These data suggested that Tim-3 could be used as a potentially significant checkpoint receptor for future anti-tumor therapy,and summarized the ongoing clinical trials of drugs,indicating that Tim-3 can be used as a potential checkpoint receptor for future anti-tumor therapy.

关 键 词：T细胞免疫球蛋白和黏蛋白结构域3 肿瘤免疫微环境 免疫抑制性受体 肿瘤 预后标志物 临床应用 

分 类 号：R457.2[医药卫生—治疗学] R730.23[医药卫生—临床医学] Q813[生物学—生物工程]